Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
About the study
This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance and/or uncontrolled systolic hypertension.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Shows lack of cortisol suppression
- Suppressed or low early-morning ACTH levels
- A radiologically confirmed adrenal lesion
- Has IGT or DM
- Has uncontrolled hypertension
EXCLUSION CRITERIA
Exclusion Criteria:
- Has severe, uncontrolled hypertension
- Has poorly controlled DM
- Has DM Type 1
- Has significantly abnormal liver test results or severe renal insufficiency
- Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Hypercortisolism
Age (in years)
18 - 80
Phase
Phase 3
Participants needed
130
Est. Completion Date
Oct 31, 2023
Treatment type
Interventional
Sponsor
Corcept Therapeutics
ClinicalTrials.gov identifier
NCT04308590
Study number
CORT125134-456
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?